CClinicalTrials.gg
RecruitingNCT07614386RADIUSUpdated Jun 23, 2026

Radial Access Data in Vascular Interventions Registry

An observational study in Radial Artery Occlusion, Radial Artery Spasm and Vascular Access Complications, sponsored by Mersin Medicalpark Hastanesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Mersin Medicalpark Hastanesi · Observational

From the registry’s dates

  • Started May 2026; still recruiting 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Study summary

The RADIUS study is a prospective observational registry designed to collect real-world data regarding radial and ulnar artery access in percutaneous vascular interventions. The study aims to evaluate procedural characteristics, access-site complications, procedural success, and short-term clinical outcomes associated with transradial and transulnar vascular access.

Patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access at Mersin Medical Park Hospital will be consecutively enrolled. Demographic, clinical, angiographic, procedural, and post-procedural data will be prospectively collected and analyzed.

The study was initially designed as a single-center registry; however, following Institutional Review Board (IRB) approval, expansion into a multicenter registry with participating centers is planned.

This study is observational in nature and does not involve any experimental treatment, device, or intervention beyond standard clinical care.

Read the detailed description

The RADIUS (Radial Access Data in Vascular Interventions) study is a prospective observational registry designed to systematically collect real-world data regarding radial and ulnar artery access in percutaneous vascular interventions.

Transradial access has become increasingly preferred in contemporary interventional practice because of lower bleeding risk, improved patient comfort, earlier mobilization, and reduced vascular complications compared with traditional femoral access. In addition, transulnar access has emerged as an alternative vascular access strategy in selected patients. Despite the increasing adoption of radial and ulnar access techniques, comprehensive real-world registry data evaluating procedural characteristics, vascular complications, procedural success, and clinical outcomes remain limited.

The RADIUS registry aims to evaluate demographic, clinical, angiographic, procedural, and post-procedural characteristics of patients undergoing percutaneous vascular interventions through radial or ulnar artery access. Particular focus will be placed on access-site complications, including radial artery spasm, radial artery occlusion, bleeding complications, crossover to alternative access sites, vascular injury, and short-term clinical outcomes.

The study will enroll consecutive adult patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access at Mersin Medical Park Hospital between May 2026 and May 2031. Data will be prospectively collected from procedural reports, hospital electronic medical records, and routine clinical evaluations.

Collected variables will include demographic characteristics, cardiovascular risk factors, comorbidities, laboratory findings, angiographic and procedural details, vascular access characteristics, procedural duration, fluoroscopy time, contrast volume, devices and techniques used during procedures, procedural success rates, and in-hospital and short-term complications.

The study was initially designed as a single-center registry; however, expansion into a multicenter registry involving additional participating centers is planned following Institutional Review Board (IRB) approval and local regulatory processes.

This registry is purely observational in nature and does not involve any experimental drug, device, or intervention beyond standard clinical care. All procedures and treatment strategies will be performed according to current routine clinical practice and operator discretion.

Data obtained from the registry will be analyzed using appropriate statistical methods, and the results are expected to contribute to the understanding and optimization of radial and ulnar access strategies in vascular interventions and support future scientific publications.

02

Conditions studied

  • Radial Artery Occlusion
  • Radial Artery Spasm
  • Vascular Access Complications
  • Coronary Artery Disease
  • Peripheral Arterial Disease

Keywords

  • Radial access
  • Ulnar access
  • Transradial intervention
  • Coronary angiography
  • Percutaneous coronary intervention
  • Vascular complications
  • Radial artery occlusion
  • Radial Artery Spasm
  • Registry
03

In context

Arterial Occlusive Diseases

296 studies on the registry are indexed under Arterial Occlusive Diseases; 46 are open to participants now.

This study's planned enrollment of 20,000 is above the median of 183 across 75 observational studies indexed under Arterial Occlusive Diseases.

Browse Arterial Occlusive Diseases studies →

Lead sponsor

Mersin Medicalpark Hastanesi is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access.

Inclusion criteria

  • Age ≥18 years
  • Patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access
  • Ability to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Procedures performed without radial or ulnar artery access
  • Incomplete procedural or clinical data
  • Refusal to participate in the registry
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Radial and Ulnar Access Registry Cohort

    Patients undergoing routine percutaneous vascular interventions via radial or ulnar artery access.

    Procedure: Radial and Ulnar Artery Access

Interventions

  • ProcedureRadial and Ulnar Artery Access

    Routine percutaneous vascular interventions performed via radial or ulnar artery access according to standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Radial Artery Occlusion Rate

    Incidence of radial artery occlusion following percutaneous vascular interventions performed via radial artery access.

    Time frame: Within 1 year after procedure

  2. Access-Site Vascular Complication Rate

    Incidence of vascular access-site complications including bleeding, hematoma, pseudoaneurysm, arterial dissection, and vascular injury.

    Time frame: through study completion, an average of 1 year

  3. Radial Artery Spasm Rate

    Incidence of clinically significant radial artery spasm during or immediately after the procedure.

    Time frame: During Procedure

Secondary outcomes

  1. Procedural Success Rate

    Successful completion of the planned vascular intervention using radial or ulnar artery access without crossover to alternative access.

    Time frame: During procedure

  2. Crossover Rate

    Need for conversion from radial or ulnar access to another vascular access site during the procedure.

    Time frame: During Procedure

  3. Bleeding Complications

    Incidence of access-site or non-access-site bleeding complications following the procedure.

    Time frame: During Procedure

  4. Fluoroscopy Time

    Total fluoroscopy time during the procedure, measured in minutes.

    Time frame: During Procedure

  5. Length of Hospital Stay

    Duration of hospitalization following vascular intervention, measured in days from the date of the procedure until hospital discharge.

    Time frame: From the date of vascular intervention until hospital discharge, assessed up to 30 days

  6. Contrast Volume

    Total volume of contrast agent administered during the procedure, measured in milliliters (mL).

    Time frame: During Procedure

07

Study locations

1 of 1 sites recruiting
  • Mersin Medicalpark hospital
    Mersin, Mezitli 33010, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make individual participant data (IPD) publicly available.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614386
Lead sponsor
Mersin Medicalpark Hastanesi
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 15, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
May 20, 2031 (estimated)
Last update
Jun 23, 2026

Study contacts

Sefa SURAL, MD
Contact
sesural@hotmail.com
+90 532 565 01 60
Gökhan AVCI, MD
Contact
drgavci@hotmail.com
+90 506 228 57 09
Sefa SURAL, MD
study director · Toros University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion